Epilepsy

A network meta-analysis of 5 third-generation antiseizure medications found that cenobamate was likely to have the best efficacy, and brivaracetam and lacosamide were likely to have the best tolerability.

A study analyzed the incidence and cognitive and functional outcomes of posttraumatic epilepsy in patients with traumatic brain injury.

Patients with adult-onset epilepsy who took enzyme-inducing antiseizure medications had a higher hazard of incident cardiovascular disease.

In 2-year-old children of women with epilepsy, no cognitive differences were seen compared with children of mothers without epilepsy.

A recent meta-analysis of clinical trials for newer antiseizure medications found that the risk of suicidality was not increased compared with placebo.

Clinical effectiveness and cost-effectiveness may favor lamotrigine over newer antiseizure treatments levetiracetam and zonisamide for focal epilepsy.

In a study with important implications for first-line treatment of generalized epilepsy, particularly for women of childbearing age, investigators found that levetiracetam may not be as clinically effective or cost-effective as valproate for newly diagnosed generalized epilepsy.

The safety profile for diazepam nasal spray for acute treatment of seizure clusters was similar with or without concomitant benzodiazepine therapy, according to the interim results of a phase 3 open-label safety study.

Brivaracetam as adjunctive therapy for focal seizures is safe, well-tolerated, and efficacious, according to the results of a long-term follow-up study of participants in earlier clinical trials.